News

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

ipharmaservices

16 hours ago

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

Badari Andukuri

19 hours ago

US–Swiss Tariff Cap Impact on Pharma: How the New US–Swiss Tariff Cap Shapes Pharma and Health Security

ipharmaservices

20 hours ago

NICE’s New £35k/QALY Era: Ripple Effects for Australia’s PBS and Other HTA Markets | NICE Cost Effectiveness Threshold | iPharmaCenter

Badari Andukuri

21 hours ago

NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY

Badari Andukuri

1 day ago

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

Badari Andukuri

1 day ago

FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

ipharmaservices

1 day ago

Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

Badari Andukuri

3 days ago

EU clears Dupixent as first targeted CSU therapy in over a decade | iPharmaCenter

ipharmaservices

3 days ago

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

ipharmaservices

4 days ago

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Badari Andukuri

4 days ago

CMS Projects Billions in Future Savings for Seniors; Maximum Fair Price (MFP) Negotiation Policy Originated Under Biden Administration | iPharmaCenter

ipharmaservices

6 days ago

CMS Introduces Proposed Rule to Elevate Quality and Access in Medicare Advantage and Part D | iPharmaCenter

ipharmaservices

7 days ago

NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter

ipharmaservices

Nov 25

Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)

ipharmaservices

Nov 25

The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter

Badari Andukuri

Nov 24

Germany Signals Major Health System Overhaul as Minister Warken Warns of Growing Deficits | iPharmaCenter

ipharmaservices

Nov 23

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

ipharmaservices

Nov 23

Novartis hopes its cancer drugs drive revenues until 2030 | iPharmaCenter

Badari Andukuri

Nov 23

Roche’s Giredestrant Leads the Way as First Oral SERD to Improve Outcomes in Early Breast Cancer | iPharmaCenter

ipharmaservices

Nov 19